Literature DB >> 3281618

The effect of beta-blockers on mental performance on older hypertensive patients.

F M Gengo1, S C Fagan, A de Padova, J K Miller, P R Kinkel.   

Abstract

This double-blind, three-way crossover study measured the influence of beta-blocker treatment on drowsiness and mental test performance in older hypertensive patients and determined if lipophilicity was a determinant of these effects. Twenty-seven hypertensive patients (mean age, 63 +/- 3 years) were studied. Patients received two weeks each of daily treatment with placebo, 100 mg of atenolol, or 150 mg of metoprolol tartrate and were evaluated on the 14th day of each treatment period, after which their next treatment period began. Mental performance was measured using Trails-A maze testing. Drowsiness was measured subjectively using a visual analogue scale, and objectively using critical fusion-frequency threshold testing. Blood pressure control was equivalent and clinically adequate in all subjects. Steady-state levels of metoprolol tartrate (235.7 +/- 46 ng/mL) and atenolol (453.6 +/- 56 ng/nL) achieved were those expected to produce similar beta-blockade. Mental performance as measured by Trials-A testing showed better scores during beta-blocker treatment compared with placebo. Trails-A scores improved as patients went from placebo to metoprolol treatment, but did not change as patients went from placebo to atenolol treatment. Critical fusion-frequency threshold measurements were lower following administration of both drugs than following that of placebo, but subjectively there was no difference in feelings of lethargy between either beta-blocker and placebo. These data show greater improvement in mental testing performance to be associated with metoprolol treatment, but neither produced more lethargy than placebo in elderly patients.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3281618

Source DB:  PubMed          Journal:  Arch Intern Med        ISSN: 0003-9926


  15 in total

1.  Cognitive impairment associated with beta-blockade in the elderly.

Authors:  T K Rogers; C E Bowman
Journal:  Postgrad Med J       Date:  1990-12       Impact factor: 2.401

Review 2.  Antihypertensive medications and depression.

Authors:  M H Beers; L J Passman
Journal:  Drugs       Date:  1990-12       Impact factor: 9.546

3.  Subjective symptoms and pharmacokinetics/dynamics of metoprolol CR in elderly subjects--a comparison with atenolol.

Authors:  E S Dimenäs; C G Dahlöf; B Heibel; R G Moore; B K Olofsson; G E Westergren; P W Lücker
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

Review 4.  Atenolol. A reappraisal of its pharmacological properties and therapeutic use in cardiovascular disorders.

Authors:  A N Wadworth; D Murdoch; R N Brogden
Journal:  Drugs       Date:  1991-09       Impact factor: 9.546

Review 5.  Therapeutic uses of beta-adrenoceptor blocking drugs in the central nervous system in man.

Authors:  P Turner
Journal:  Postgrad Med J       Date:  1989-01       Impact factor: 2.401

6.  CNS-related subjective symptoms during treatment with beta 1-adrenoceptor antagonists (atenolol, metoprolol): two double-blind placebo controlled studies.

Authors:  E Dimenäs; C Dahlöf; B Olofsson; I Wiklund
Journal:  Br J Clin Pharmacol       Date:  1989-11       Impact factor: 4.335

7.  Cognitive function in hypertensives treated with atenolol or propranolol.

Authors:  D M Palac; R D Cornish; W J McDonald; D A Middaugh; D Howieson; S P Bagby
Journal:  J Gen Intern Med       Date:  1990 Jul-Aug       Impact factor: 5.128

Review 8.  Beta-adrenergic function in aging. Basic mechanisms and clinical implications.

Authors:  P J Scarpace; N Tumer; S L Mader
Journal:  Drugs Aging       Date:  1991-03       Impact factor: 3.923

9.  Documentation of an instrument for assessment of subjective CNS-related symptoms during cardiovascular pharmacotherapy.

Authors:  C Dahlöf; E Dimenäs; B Olofsson
Journal:  Cardiovasc Drugs Ther       Date:  1989-12       Impact factor: 3.727

10.  Effects of diltiazem and metoprolol on blood pressure, adverse symptoms and general well-being. The Swedish Diltiazem-Metoprolol Multi-Centre Study Group.

Authors:  C Dahlöf; T Hedner; T Thulin; S Gustafsson; S O Olsson
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.